Sanford Bernstein Strategic Decisions Conference 2013

PepsiCo CEO slams ‘maniacal’ cola focus, says Stevia does not suit category


- Last updated on GMT

Picture Copyright: Matt/Flickr
Picture Copyright: Matt/Flickr

Related tags Coca-cola Soft drink

PepsiCo CEO Indra Nooyi believes a ‘maniacal focus’ on cola's woes is unhelpful within the US beverage market, and despite the firm’s heavy investment in Rebaudioside D-based sweetener innovation, claims Stevia ‘does not work well in colas’.

Nooyi made her surprisingly candid remarks during an address at the Sanford Bernstein Strategic Decisions Conference in New York yesterday.

Sanford Bernstein analyst, Ali Dibadj, asked Nooyi whether trends within PepsiCo Americas Beverages (PAB), with volume sales down 5% in Q1 2013, pricing up 5%, were secular or cyclical?

PepsiCo’s boss replied it was important to talk about liquid refreshment beverages (LRBs) as a whole and not just carbonated soft drinks (CSD).

She noted that 60% of the $100bn US market for LRBs involved non-CSDs, while within carbonates colas were a smaller percentage and declining.

“So I think there is a maniacal focus on cola that is not the right way to look at a beverage market that is so huge,”​ Nooyi said.

‘Irrational behaviour in marketplace’

Hinting at PepsiCo’s plan to pursue ‘hybrid everyday value pricing’ for LRBs across the US – to build value and stop the bulk of sales being squeezed into heavy promotional periods during vacation periods – Nooyi said it was “very important that all the players play a sensible game in this business”.

“I think short-term pricing action to pursue volume is a wrong strategy in this sort of market, and the more people focus on carbonated soft drink volume and the more people focus on cola volume, you’re going to see more irrational behaviour in the marketplace.”

Despite payroll tax distress in the US and poor weather that hit PAB in Q1, Nooyi said the market was shifting more to non-cola beverages like Mountain Dew, but said the cola category had not seen much by way of innovation.

“So I look at…what we’re doing in R&D, in a big profitable category with lots of US cashflow. Let’s see how the game plays out.”

‘I didn’t say Stevia or Reb D. Good try.’

Nooyi said that – contrary to some investors and sell-side analysts three years ago – she predicted that CSDs would decline in the US, and that she drove PepsiCo to invest in technology as a result.

“When we go and talk to consumers especially in the US, they love the bubbles, they love the caffeine, they love the taste of cola. What do they not like? They don’t like the sugar levels. And recently they don’t like artificial sweeteners,”​ she added.

Claiming that “Stevia unfortunately does not work well in colas”​, Nooyi said PepsiCo developed mid-calorie option Pepsi NEXT, which she claimed was “holding its own”​ and had found a niche.

Work the firm was doing with natural sweeteners and flavoring agents could address barriers to consumption “while the consumer still remains in love with CSDs”​ and bring back lapsed users.

But Nooyi refused to be drawn by Dibadj’s observation that PepsiCo was “placing a lot of weight on this Stevia-based Reb D”​.

“I didn’t say Stevia or Reb D. Good try,”​ Nooyi replied.

Aseptic Technology 2013 - Today!

Today, and will host an exclusive, free, online event on aseptic processing and packaging technology, Aseptic Technology 2013.  Our program includes speakers from Sidel, GEA, Coca-Cola Hellenic, Zenith International and more. The event begins at 9am New York time. Click here to register and to learn more .

Related news

Show more

Related products

show more

What consumers are looking for in alcohol drinks

What consumers are looking for in alcohol drinks

Content provided by ADM | 12-Apr-2024 | Application Note

Are you ready to understand the consumer insights driving the future of the alcoholic beverage market? We've assembled a consumer insights report...

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-Apr-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

Related suppliers

Follow us


View more